FASEB SRC on Lipids and Lipid Regulated Kinases in Cancer

描述（由申请人提供）：本提案要求部分支持美国实验生物学学会联合会（FASEB）关于“癌症中的脂质和脂质调节激酶”的夏季研究会议（SRC）。本次会议将于2014年7月27日至8月1日在科罗拉多州蒸汽船泉的蒸汽船大度假村举行。为期4天半的会议将吸引约100-120名国内外科学家参加，目的是讨论脂质调节信号转导级联、脂质介质和脂质靶点的最新突破。会议将连续举行九届专题会议，每届会议由该领域的一位杰出专家主持。FASEB夏季研究会议是世界知名的杰出机制，通过该会议，博士生、博士后研究员和新独立的研究人员等初级科学家可以与学术界和工业界的知名科学家进行互动，并公开讨论他们的工作。2014年的会议将由Mary Reyland博士和Peter Parker博士组织，这将是继2007年、2009年和2012年非常成功的会议之后的第四届FASEB SRC会议。脂质信号传导领域在癌症治疗的临床干预方面受到了极大的关注。事实上，每一条脂质信号通路都与癌症的发生、发展和/或传播有直接和因果关系，因此，许多制药和生物技术公司都有积极的药物发现项目，正在评估许多脂质信号酶作为人类癌症治疗干预的新靶点。因此，脂质信号传导途径的转化和临床意义将在每个专题会议上占据中心位置，在这些会议上，成熟的研究人员将讨论他们研究的临床和治疗后果。我们希望，作为这次会议的直接结果，新的想法和合作将会产生

DESCRIPTION (provided by applicant): This proposal requests partial support for the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference (SRC) on 'Lipids and Lipid Regulated Kinases in Cancer". Support is requested for the 2014 meeting of this conference to be held on July 27-August 1, 2014, at the Steamboat Grand Resort in Steamboat Springs, CO. This 4 1/2-day conference will attract about 100-120 participants national and international scientists with the goal of discussing the latest breakthroughs in lipid-regulated signal transduction cascades, lipid mediators, and lipid targets. The meeting will consist of nine consecutive thematic sessions, each chaired by a distinguished expert in that field. FASEB Summer Research Conference are known world-wide as an outstanding mechanism by which junior scientists such as PhD students, post- doctoral fellows and newly independent investigators can interact with and openly discuss their work with established scientists from academics and industry who are leaders in their respective fields. The 2014 conference will be organized by Dr. Mary Reyland and Dr. Peter Parker and will be the fourth FASEB SRC conference of its kind, building upon previous highly successful conferences held in 2007, 2009 and 2012. The field of lipid signaling has received enormous attention with respect to clinical intervention in cancer therapy. Virtually every lipid signaling pathway has been directly and causally linked to cancer initiation, progression and/or dissemination, and for that reason many pharmaceutical and biotechnology companies have active drug discovery programs that are evaluating many lipid signaling enzymes as novel targets for therapeutic intervention in human cancer. The translational and clinical implications of lipid signaling pathways will therefore take center stage in every thematic session where established investigators will be discussing the clinical and therapeutic ramifications of their research. Our hope is that as a direct result of this conference, new ideas and collaborations will be forged and that the new trainees and young investigators who attend will not only be exposed to many exciting areas of research, but will use the conference as a vehicle to catapult their research in exciting new directions.